Tuberculosis: Current Progress in Drug targets, Potential Drugs and Therapeutic Impact

IF 0.2 Q4 RESPIRATORY SYSTEM

Current Respiratory Medicine Reviews Pub Date : 2022-05-03 DOI:10.2174/1573398x18666220503184459

Mukesh Masand, Pramod Kumar Sharma, Vishal M. Balaramnavar, Deepti Mathpal

引用次数: 0

Abstract

The World Health Organization (WHO) considers tuberculosis to be the most dangerous chronic communicable disease in the world, infecting two billion people or one-third of the world’s population. Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a leading cause of mortality worldwide into the 21st century. Tuberculosis is second only to AIDS among other infectious diseases in causing deaths worldwide. The emergence of AIDS, multidrug-resistant TB (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB), the decline of socioeconomic standards, and a reduced emphasis on tuberculosis control programmers contribute to the disease’s resurgence in industrialized countries.

查看原文本刊更多论文

结核病：药物靶点、潜在药物和治疗效果的最新进展

世界卫生组织(世卫组织)认为结核病是世界上最危险的慢性传染病，感染了20亿人，占世界人口的三分之一。结核分枝杆菌引起的结核病(TB)仍然是21世纪世界范围内死亡的主要原因。在全世界造成死亡的其他传染病中，结核病仅次于艾滋病。艾滋病、耐多药结核病(MDR-TB)、广泛耐药结核病(XDR-TB)的出现、社会经济标准的下降以及对结核病控制规划的重视程度降低，都是导致该疾病在工业化国家死灰复燃的原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Respiratory Medicine Reviews RESPIRATORY SYSTEM-

CiteScore

0.60

自引率

0.00%

发文量

期刊介绍： Current Respiratory Medicine Reviews publishes frontier reviews on all the latest advances on respiratory diseases and its related areas e.g. pharmacology, pathogenesis, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in respiratory medicine.